207 related articles for article (PubMed ID: 24837469)
1. A unique case of refractory primary mediastinal B-cell lymphoma with JAK3 mutation and the role for targeted therapy.
Hanna DM; Fellowes A; Vedururu R; Mechinaud F; Hansford JR
Haematologica; 2014 Sep; 99(9):e156-8. PubMed ID: 24837469
[No Abstract] [Full Text] [Related]
2. Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutation.
Gomez-Arteaga A; Margolskee E; Wei MT; van Besien K; Inghirami G; Horwitz S
Leuk Lymphoma; 2019 Jul; 60(7):1626-1631. PubMed ID: 30997845
[No Abstract] [Full Text] [Related]
3. Hitting back at lymphoma: How do modern diagnostics identify high-risk diffuse large B-cell lymphoma subsets and alter treatment?
Abramson JS
Cancer; 2019 Sep; 125(18):3111-3120. PubMed ID: 31287161
[TBL] [Abstract][Full Text] [Related]
4. The management of primary mediastinal B-cell lymphoma with sclerosis.
Brugger W; Engelhardt R; Mertelsmann R; Kanz L
Ann Oncol; 1994 Dec; 5(10):943-7. PubMed ID: 7535081
[No Abstract] [Full Text] [Related]
5. A single-institution retrospective analysis of outcomes for stage I-II primary mediastinal large B-cell lymphoma treated with immunochemotherapy with or without radiotherapy.
Binkley MS; Hiniker SM; Wu S; Natkunam Y; Mittra ES; Advani RH; Hoppe RT
Leuk Lymphoma; 2016; 57(3):604-8. PubMed ID: 26159046
[TBL] [Abstract][Full Text] [Related]
6. Tofacitinib as the potent treatment for refractory pemphigus: A possible alternative treatment for pemphigus.
Tavakolpour S
Dermatol Ther; 2018 Sep; 31(5):e12696. PubMed ID: 30207045
[TBL] [Abstract][Full Text] [Related]
7. Primary mediastinal large B-cell lymphoma.
Savage KJ
Oncologist; 2006 May; 11(5):488-95. PubMed ID: 16720849
[TBL] [Abstract][Full Text] [Related]
8. Loss of function mutations in PTPN6 promote STAT3 deregulation via JAK3 kinase in diffuse large B-cell lymphoma.
Demosthenous C; Han JJ; Hu G; Stenson M; Gupta M
Oncotarget; 2015 Dec; 6(42):44703-13. PubMed ID: 26565811
[TBL] [Abstract][Full Text] [Related]
9. JAK inhibitors: treatment efficacy and safety profile in patients with psoriasis.
Hsu L; Armstrong AW
J Immunol Res; 2014; 2014():283617. PubMed ID: 24883332
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of pleural or pericardial effusion and the implication of optimal treatment in primary mediastinal large B-cell lymphoma: a multicenter retrospective study in Japan.
Aoki T; Izutsu K; Suzuki R; Nakaseko C; Arima H; Shimada K; Tomita A; Sasaki M; Takizawa J; Mitani K; Igarashi T; Maeda Y; Fukuhara N; Ishida F; Niitsu N; Ohmachi K; Takasaki H; Nakamura N; Kinoshita T; Nakamura S; Ogura M
Haematologica; 2014 Dec; 99(12):1817-25. PubMed ID: 25216682
[TBL] [Abstract][Full Text] [Related]
11. Primary mediastinal large B-cell lymphoma.
Bhatt VR; Mourya R; Shrestha R; Armitage JO
Cancer Treat Rev; 2015 Jun; 41(6):476-85. PubMed ID: 25913715
[TBL] [Abstract][Full Text] [Related]
12. Improvement of lymphangioleiomyomatosis following successful tofacitinib treatment for refractory synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome.
Liu S; Li C; Tang MW; Xu WS; Chen KQ; Sui X; Tian XL; Xu KF
Chin Med J (Engl); 2019 Oct; 132(19):2378-2379. PubMed ID: 31503058
[No Abstract] [Full Text] [Related]
13. Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study.
Zinzani PL; Stefoni V; Finolezzi E; Brusamolino E; Cabras MG; Chiappella A; Salvi F; Rossi A; Broccoli A; Martelli M
Clin Lymphoma Myeloma; 2009 Oct; 9(5):381-5. PubMed ID: 19858058
[TBL] [Abstract][Full Text] [Related]
14. Ruxolitinib shows activity against Hodgkin lymphoma but not primary mediastinal large B-cell lymphoma.
Kim SJ; Yoon DH; Kang HJ; Hong JY; Lee HS; Oh SY; Shin HJ; Kong JH; Yi JH; Sakamoto K; Ko YH; Huh J; Lee SS; Takeuchi K; Shin DY; Suh C; Kim WS
BMC Cancer; 2019 Nov; 19(1):1080. PubMed ID: 31707975
[TBL] [Abstract][Full Text] [Related]
15. [Large-cell mediastinal lymphoma].
Gori E; Tata F; Zanna M; Bruzzone G
Clin Ter; 1991 Oct 15-31; 139(1-2):45-8. PubMed ID: 1837766
[TBL] [Abstract][Full Text] [Related]
16. Primary Mediastinal Large B-Cell Lymphoma As an Incidental Finding: Report of a Case.
Yönal-Hindilerden İ; Hindilerden F; Arslan S; Doğan İÖ; Nalçacı M
Turk J Haematol; 2018 May; 35(2):141-142. PubMed ID: 27094863
[No Abstract] [Full Text] [Related]
17. Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R.
Giulino-Roth L; O'Donohue T; Chen Z; Bartlett NL; LaCasce A; Martin-Doyle W; Barth MJ; Davies K; Blum KA; Christian B; Casulo C; Smith SM; Godfrey J; Termuhlen A; Oberley MJ; Alexander S; Weitzman S; Appel B; Mizukawa B; Svoboda J; Afify Z; Pauly M; Dave H; Gardner R; Stephens DM; Zeitler WA; Forlenza C; Levine J; Williams ME; Sima JL; Bollard CM; Leonard JP
Br J Haematol; 2017 Dec; 179(5):739-747. PubMed ID: 29082519
[TBL] [Abstract][Full Text] [Related]
18. Primary mediastinal large B-cell lymphoma.
Faris JE; LaCasce AS
Clin Adv Hematol Oncol; 2009 Feb; 7(2):125-33. PubMed ID: 19367254
[TBL] [Abstract][Full Text] [Related]
19. Targeting JAK3 in kidney transplantation: current status and future options.
Wojciechowski D; Vincenti F
Curr Opin Organ Transplant; 2011 Dec; 16(6):614-9. PubMed ID: 21971513
[TBL] [Abstract][Full Text] [Related]
20. High-dose chemotherapy for relapsed and refractory diffuse large B-cell lymphoma: mediastinal localization predicts for a favorable outcome.
Popat U; Przepiork D; Champlin R; Pugh W; Amin K; Mehra R; Rodriguez J; Giralt S; Romaguera J; Rodriguez A; Preti A; Andersson B; Khouri I; Claxton D; de Lima M; Donato M; Anderlini P; Gajewski J; Cabanillas F; van Besien K
J Clin Oncol; 1998 Jan; 16(1):63-9. PubMed ID: 9440724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
